Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/2/2016 |
| Start Date: | August 2003 |
| End Date: | September 2008 |
| Contact: | Billy Jimenez |
| Email: | billy.jiminez@va.gov |
| Phone: | (505) 265-1711 |
The purpose of this study is the use of magnetoencephalography or MEG (a machine that
measures magnetic activity in your brain) and electroencephalography or EEG (a technique
that measures electrical activity in your brain) to study how sounds are processed in
individuals with schizophrenia prior to initiation with aripiprazole treatment and after
three months of taking the antipsychotic medication aripiprazole.
measures magnetic activity in your brain) and electroencephalography or EEG (a technique
that measures electrical activity in your brain) to study how sounds are processed in
individuals with schizophrenia prior to initiation with aripiprazole treatment and after
three months of taking the antipsychotic medication aripiprazole.
Problems with attention and perception are core features of schizophrenia and are
hypothesized to result from defects in the filtering or gating of sensory input. Examination
of this requires neuroimaging techniques with high temporal resolution. High-density EEG and
MEG in combination with structural magnetic resonance imaging (sMRI) are used to map sensory
gating. In a number of recent studies patient treated with novel antipsychotics have been
shown to have P50 gating ratios resembling those of normal controls rather than that of
schizophrenia subjects treatment with conventional antipsychotics. To date, there is no
literature on the effects of aripiprzole on sensory gating. Subjects who meet all inclusion
criteria will receive a clinical interview, an MRI, MEG, and neuropsychological testing
before starting treatment with aripiprazole and again 3 months later to determine if
patients with schizophrenia who are treated with aripiprazole will demonstrate a sensory
gating ratio similar to normal controls, indicating no deficit in sensory gating
hypothesized to result from defects in the filtering or gating of sensory input. Examination
of this requires neuroimaging techniques with high temporal resolution. High-density EEG and
MEG in combination with structural magnetic resonance imaging (sMRI) are used to map sensory
gating. In a number of recent studies patient treated with novel antipsychotics have been
shown to have P50 gating ratios resembling those of normal controls rather than that of
schizophrenia subjects treatment with conventional antipsychotics. To date, there is no
literature on the effects of aripiprzole on sensory gating. Subjects who meet all inclusion
criteria will receive a clinical interview, an MRI, MEG, and neuropsychological testing
before starting treatment with aripiprazole and again 3 months later to determine if
patients with schizophrenia who are treated with aripiprazole will demonstrate a sensory
gating ratio similar to normal controls, indicating no deficit in sensory gating
Inclusion Criteria:
Patient Population
- Diagnosis of Schizophrenia as determine by the Structured Clinical Interview for
DSM-IV
- no comorbid diagnosis of PTSD
- continuous treatment with a conventional antipsychotic, risperidone or olanzapine for
at least 3 months
- absence of psychiatric hospitalization for at least 3 month
- no history of drug dependency in their lifetime
- no history of alcohol or other substance abuse in the 6 months prior to entry into
the study
- no history of head injury with loss of consciousness for more than 5 minutes
- no history of seizure disorder
- no mood stabilizing agents
- between 18-65 and
- able to sign informed consent
Normal Controls
- Matched in age and gender to patient population
- No history of psychiatric dysfunction or alcohol or other substance dependence in
their lifetime as determine by the SCID
- No history of alcohol or other substance abuse in the previous 6 months
- No family history of psychotic disorder in first degree relatives as assessed by the
FH-RDC diagnostic interview
- No history of head injury with loss of consciousness for more than 5 minutes
- No history of seizure disorder
- Between 18-65
- Able to sign informed consent
Exclusion Criteria:
Subjects will be excluded from participating in this study if they:
- Require treatment with a mood stabilizer
- Have had an inpatient hospitalization in the past 3 months\
- Have a history of a neurological disorder
- Have any other axis I diagnosis besides schizophrenia
We found this trial at
1
site
Click here to add this to my saved trials
